{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:26:25Z","timestamp":1794245185046,"version":"4.9.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Abnormal glycosylation is a hallmark of cancer, and the hypersialylated tumor cell surface facilitates abnormal cell trafficking and drug resistance in several malignancies, including multiple myeloma (MM). Furthermore, hypersialylation has also been implicated in facilitating evasion of natural killer (NK) cell\u2013mediated immunosurveillance but not in MM to date. In this study, we explore the role of hypersialylation in promoting escape from NK cells. We document strong expression of sialic acid-derived ligands for Siglec-7 (Siglec-7L) on primary MM cells and MM cell lines, highlighting the possibility of Siglec-7\/Siglec-7L interactions in the tumor microenvironment. Interactomics experiments in MM cell lysates revealed PSGL-1 as the predominant Siglec-7L in MM. We show that desialylation, using both a sialidase and sialyltransferase inhibitor (SIA), strongly enhances NK cell\u2013mediated cytotoxicity against MM cells. Furthermore, MM cell desialylation results in increased detection of CD38, a well-validated target in MM. Desialylation enhanced NK cell cytotoxicity against CD38+ MM cells after treatment with the anti-CD38 monoclonal antibody daratumumab. Additionally, we show that MM cells with low CD38 expression can be treated with all trans-retinoic acid (ATRA), SIA and daratumumab to elicit a potent NK cell cytotoxic response. Finally, we demonstrate that Siglec-7KO potentiates NK cell cytotoxicity against Siglec-7L+ MM cells. Taken together, our work shows that desialylation of MM cells is a promising novel approach to enhance NK cell efficacy against MM, which can be combined with frontline therapies to elicit a potent anti-MM response.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006805","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T15:18:56Z","timestamp":1647443936000},"page":"3352-3366","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":96,"title":["Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell\u2013mediated tumor responses"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-0473","authenticated-orcid":false,"given":"John","family":"Daly","sequence":"first","affiliation":[{"name":"1Apoptosis Research Center, National University of Ireland, Galway, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Sarkar","sequence":"additional","affiliation":[{"name":"1Apoptosis Research Center, National University of Ireland, Galway, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-9005","authenticated-orcid":false,"given":"Alessandro","family":"Natoni","sequence":"additional","affiliation":[{"name":"1Apoptosis Research Center, National University of Ireland, Galway, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3828-5438","authenticated-orcid":false,"given":"Jessica C.","family":"Stark","sequence":"additional","affiliation":[{"name":"2Department of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-2966","authenticated-orcid":false,"given":"Nicholas M.","family":"Riley","sequence":"additional","affiliation":[{"name":"2Department of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4482-2754","authenticated-orcid":false,"given":"Carolyn R.","family":"Bertozzi","sequence":"additional","affiliation":[{"name":"2Department of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA;"},{"name":"3Howard Hughes Medical Institute, Stanford University, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9815-0012","authenticated-orcid":false,"given":"Mattias","family":"Carlsten","sequence":"additional","affiliation":[{"name":"4Center for Haematology and Regenerative Medicine (HERM), Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-7140","authenticated-orcid":false,"given":"Michael E.","family":"O'Dwyer","sequence":"additional","affiliation":[{"name":"1Apoptosis Research Center, National University of Ireland, Galway, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"2022060615220589900_B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/glycob\/cwv097","article-title":"Sialic acids in cancer biology and immunity","volume":"26","author":"Pearce","year":"2016","journal-title":"Glycobiology."},{"issue":"23","key":"2022060615220589900_B2","doi-asserted-by":"crossref","first-page":"35478","DOI":"10.18632\/oncotarget.8155","article-title":"Hallmarks of glycosylation in cancer","volume":"7","author":"Munkley","year":"2016","journal-title":"Oncotarget."},{"key":"2022060615220589900_B3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1023\/A:1022288022969","article-title":"Sialyltransferases in cancer","volume":"18","author":"Dall'Olio","year":"2001","journal-title":"Glycoconj."},{"issue":"11","key":"2022060615220589900_B4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2014-03-560862","article-title":"The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma","volume":"124","author":"Glavey","year":"2014","journal-title":"Blood."},{"issue":"12","key":"2022060615220589900_B5","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1158\/0008-5472.CAN-14-0728","article-title":"Sialic acids sweeten a tumor\u2019s life","volume":"74","author":"B\u00fcll","year":"2014","journal-title":"Cancer Res."},{"key":"2022060615220589900_B6","first-page":"238","article-title":"Sweet escape: sialic acids in tumor immune evasion","volume":"1846","author":"B\u00fcll","year":"2014","journal-title":"Rev Can."},{"issue":"2","key":"2022060615220589900_B7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.hemonc.2014.11.006","article-title":"Natural killer cells: in health and disease","volume":"8","author":"Mandal","year":"2015","journal-title":"Hematol Oncol Stem Cell Ther."},{"issue":"1","key":"2022060615220589900_B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","article-title":"Natural killer cell cytotoxicity: how do they pull the trigger?","volume":"128","author":"Topham","year":"2009","journal-title":"Immunology."},{"issue":"5","key":"2022060615220589900_B9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0952-7915(02)00380-1","article-title":"Variable receptors controlling activation and inhibition of NK cells","volume":"14","author":"McQueen","year":"2002","journal-title":"Curr Opin Immunol."},{"issue":"9","key":"2022060615220589900_B10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/glycob\/cwr087","article-title":"Since there are PAMPs and DAMPs, there must be SAMPs? Glycan \u201cself-associated molecular patterns\u201d dampen innate immunity, but pathogens can mimic them","volume":"21","author":"Varki","year":"2011","journal-title":"Glycobiology."},{"key":"2022060615220589900_B11","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3389\/fimmu.2018.02807","article-title":"Modulation of immune tolerance via Siglec-sialic acid interactions","volume":"9","author":"L\u00fcbbers","year":"2018","journal-title":"Front Immunol."},{"issue":"3","key":"2022060615220589900_B12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-3083.2002.01053.x","article-title":"NK cells, MHC class I molecules and the missing self","volume":"55","author":"K\u00e4rre","year":"2002","journal-title":"Scand J Immunol."},{"issue":"4","key":"2022060615220589900_B13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol."},{"issue":"7","key":"2022060615220589900_B14","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/eji.200636195","article-title":"You say ITAM and I say ITIM, let\u2019s call the whole thing off: the ambiguity of immunoreceptor signalling","volume":"36","author":"Barrow","year":"2006","journal-title":"Eur J Immunol."},{"key":"2022060615220589900_B15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3389\/fimmu.2019.01047","article-title":"Sugar free: novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer","volume":"10","author":"Daly","year":"2019","journal-title":"Front Immunol."},{"issue":"29","key":"2022060615220589900_B16","doi-asserted-by":"crossref","first-page":"22121","DOI":"10.1074\/jbc.M002788200","article-title":"Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes","volume":"275","author":"Zhang","year":"2000","journal-title":"J Biol Chem."},{"issue":"48","key":"2022060615220589900_B17","doi-asserted-by":"crossref","first-page":"34089","DOI":"10.1074\/jbc.274.48.34089","article-title":"Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes","volume":"274","author":"Nicoll","year":"1999","journal-title":"J\u00a0Biol Chem."},{"issue":"4","key":"2022060615220589900_B18","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1172\/JCI65899","article-title":"Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance","volume":"124","author":"Jandus","year":"2014","journal-title":"J Clin Invest."},{"issue":"11","key":"2022060615220589900_B19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/glycob\/cwq116","article-title":"Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells","volume":"20","author":"Kawasaki","year":"2010","journal-title":"Glycobiology."},{"issue":"48","key":"2022060615220589900_B20","doi-asserted-by":"crossref","first-page":"33481","DOI":"10.1074\/jbc.M114.593129","article-title":"Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs","volume":"289","author":"L\u00e4ubli","year":"2014","journal-title":"J Biol Chem."},{"issue":"5","key":"2022060615220589900_B21","doi-asserted-by":"crossref","first-page":"e2015024118","DOI":"10.1073\/pnas.2015024118","article-title":"Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7","volume":"118","author":"Wisnovsky","year":"2021","journal-title":"Proc Natl Acad Sci USA."},{"issue":"13","key":"2022060615220589900_B22","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1158\/1538-7445.AM2018-2713","article-title":"Preclinical development of first-in-class antibodies targeting Siglec-9 immune checkpoint for cancer immunotherapy","volume":"78","author":"B\u00e9nac","year":"2018","journal-title":"Am Assoc Cancer Res."},{"issue":"9","key":"2022060615220589900_B23","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.4049\/jimmunol.1100605","article-title":"Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9","volume":"188","author":"Miyazaki","year":"2012","journal-title":"J Immunol."},{"issue":"11","key":"2022060615220589900_B24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ni.3552","article-title":"The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9","volume":"17","author":"Beatson","year":"2016","journal-title":"Nat Immunol."},{"issue":"39","key":"2022060615220589900_B25","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.1409580111","article-title":"Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer","volume":"111","author":"L\u00e4ubli","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"issue":"27","key":"2022060615220589900_B26","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1073\/pnas.1309417110","article-title":"B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention","volume":"110","author":"Huang","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2022060615220589900_B27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol."},{"issue":"37","key":"2022060615220589900_B28","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1073\/pnas.1608069113","article-title":"Precision glycocalyx editing as a strategy for cancer immunotherapy","volume":"113","author":"Xiao","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7","key":"2022060615220589900_B29","first-page":"1746","article-title":"Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-\u03b1","volume":"54","author":"Drach","year":"1994","journal-title":"Cancer Res."},{"key":"2022060615220589900_B30","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia."},{"issue":"3","key":"2022060615220589900_B31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov."},{"issue":"8","key":"2022060615220589900_B32","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1021\/acscentsci.1c00064","article-title":"Modulation of Siglec-7 signaling via in situ-created high-affinity cis-ligands","volume":"7","author":"Hong","year":"2021","journal-title":"ACS Cent Sci."},{"issue":"6","key":"2022060615220589900_B33","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","article-title":"P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"2022060615220589900_B34","doi-asserted-by":"crossref","first-page":"417586","DOI":"10.1155\/2015\/417586","article-title":"Inhibition of P-selectin and PSGL-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib","volume":"2015","author":"Muz","year":"2015","journal-title":"BioMed Res Int."},{"issue":"12","key":"2022060615220589900_B35","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1038\/leu.2017.123","article-title":"E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271","volume":"31","author":"Natoni","year":"2017","journal-title":"Leukemia."},{"issue":"1","key":"2022060615220589900_B36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nchembio.1388","article-title":"Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion","volume":"10","author":"Hudak","year":"2014","journal-title":"Nat Chem Biol."},{"issue":"21","key":"2022060615220589900_B37","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi Kararoudi","year":"2020","journal-title":"Blood."},{"issue":"10","key":"2022060615220589900_B38","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3390\/cancers11101534","article-title":"Natural killer cell therapy: a new treatment paradigm for solid tumors","volume":"11","author":"Oh","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"3","key":"2022060615220589900_B39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12026-015-8664-y","article-title":"Practical NK cell phenotyping and variability in healthy adults","volume":"62","author":"Angelo","year":"2015","journal-title":"Immunol Res."},{"key":"2022060615220589900_B40","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fimmu.2017.01444","article-title":"Restoring natural killer cell immunity against multiple myeloma in the era of new drugs","volume":"8","author":"Pittari","year":"2017","journal-title":"Front Immunol."},{"issue":"10","key":"2022060615220589900_B41","first-page":"2064","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am J Cancer Res."},{"issue":"13","key":"2022060615220589900_B42","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1158\/0008-5472.CAN-17-3376","article-title":"Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity","volume":"78","author":"B\u00fcll","year":"2018","journal-title":"Cancer Res."},{"issue":"51","key":"2022060615220589900_B43","doi-asserted-by":"crossref","first-page":"35149","DOI":"10.1074\/jbc.M114.606517","article-title":"Systemic blockade of sialylation in mice with a global inhibitor of sialyltransferases","volume":"289","author":"Macauley","year":"2014","journal-title":"J Biol Chem."},{"key":"2022060615220589900_B44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fbioe.2019.00252","article-title":"Targeted approaches to inhibit sialylation of multiple myeloma in the bone marrow microenvironment","volume":"7","author":"Natoni","year":"2019","journal-title":"Front Bioeng Biotechnol."},{"issue":"12","key":"2022060615220589900_B45","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in\u00a0vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat Chem Biol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3352\/1900158\/advancesadv2021006805.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3352\/1900158\/advancesadv2021006805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T04:08:49Z","timestamp":1674965329000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/11\/3352\/484424\/Targeting-hypersialylation-in-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006805","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]}}}